Avalyn Pharma Inc. announced the pricing of its upsized initial public offering (IPO) at $18 per share, expecting to raise $300 million before expenses. The company specializes in inhaled therapies for rare respiratory diseases, including pulmonary fibrosis, and plans to list on Nasdaq under the ticker AVLN. The IPO includes 16.67 million shares with an option for underwriters to buy an additional 2.5 million shares. This funding will support Avalyn's clinical programs advancing inhaled formulations of antifibrotic medicines aimed at improving lung function and reducing side effects.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Gold and silver prices are under pressure ahead of key U.S. retail sales data that could influence Federal Reserve interest rate decisions. Central banks, led by Poland and China, continue to boost gold reserves, adding 41 tonnes in May, supporting l...
